Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Genetic toxicity: in vitro

Currently viewing:

Administrative data

Endpoint:
in vitro gene mutation study in bacteria
Remarks:
Type of genotoxicity: gene mutation
Type of information:
experimental study
Adequacy of study:
key study
Study period:
25-03-2021 to 12-04-2021
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Remarks:
Guideline study performed under GLP. All relevant validity criteria were met.

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2021
Report date:
2021

Materials and methods

Test guidelineopen allclose all
Qualifier:
according to guideline
Guideline:
OECD Guideline 471 (Bacterial Reverse Mutation Assay)
Deviations:
no
Qualifier:
equivalent or similar to guideline
Guideline:
EU Method B.13/14 (Mutagenicity - Reverse Mutation Test Using Bacteria)
Deviations:
no
Qualifier:
equivalent or similar to guideline
Guideline:
EPA OPPTS 870.5100 - Bacterial Reverse Mutation Test (August 1998)
Deviations:
no
Qualifier:
equivalent or similar to guideline
Guideline:
JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals
Version / remarks:
Japanese Ministry of Economy, Trade and Industry, Japanese Ministry of Health, Labor and Welfare and Japanese Ministry of Agriculture, Forestry and Fisheries (24 November 2000)
Deviations:
no
Qualifier:
equivalent or similar to guideline
Guideline:
other: ICH S2(R1) guideline
Version / remarks:
June 2012 (ICH S2(R1) Federal Register
Deviations:
not specified
GLP compliance:
yes
Type of assay:
bacterial reverse mutation assay

Test material

Constituent 1
Chemical structure
Reference substance name:
1-methoxy-4-[3-methyl-4-(2-phenylethoxy)but-3-en-1-yl]benzene
EC Number:
954-543-1
Cas Number:
2489703-47-9
Molecular formula:
C20H24O2
IUPAC Name:
1-methoxy-4-[3-methyl-4-(2-phenylethoxy)but-3-en-1-yl]benzene
Test material form:
liquid
Details on test material:
- Physical state: Liquid
- Storage condition of test material: Before first opening and for short-term storage of maximum 2 months: dry area, protected from light, room temperature. After first opening and/or for long-term storage (more than 2 months); dry area, protected from light, in a refrigerator (2-8°C), under nitrogen gas in a closed container.
- Other: colourless liquid

Method

Target gene:
histidine or tryptophan locus
Species / strainopen allclose all
Species / strain / cell type:
S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
Additional strain / cell type characteristics:
not applicable
Species / strain / cell type:
E. coli WP2 uvr A pKM 101
Additional strain / cell type characteristics:
not applicable
Metabolic activation:
with and without
Metabolic activation system:
Type and composition of metabolic activation system: Rat liver S9
- source of S9: Purchased from recognised supplier (dates within full study report) ; S9 Microsomal fraction: Lot No. 4388
- method of preparation of S9 mix: Documented in the full study report. Stored at -80ºC
- concentration or volume of S9 mix and S9 in the final culture medium: 10% S9
- quality controls of S9 (e.g., enzymatic activity, sterility, metabolic capability): A Certificate of S9 QC and Production Certificate including Activity is presented in the full study report. Additionally, prior to testing each batch was subjected to in-house testing to assess batch-to-batch variation using promutagens: cyclophosphamide and benzo[a]pyrene (TA1535 and TA98, respectively) and was found to be acceptable. Furthermore, concurrent positive control substances all produced marked increases in the number of revertant colonies and the activity of the S9 fraction was found to be satisfactory.
Test concentrations with justification for top dose:
Experiment 1 (plate incorporation method):
All strains (presence of S9-mix): 0, 1.6, 5, 16, 50, 160, 500, 1600 and 5000 µg/plate
All strains (absence of S9-mix): 0, 1.6, 5, 16, 50, 160, 500, 1600 and 5000 µg/plate
On the day of dosing, precipitate was seen at and above 160 μg (0.54 μmol) per plate for all five strains in the presence and absence of S9 mix. On the day of scoring, precipitate was seen at and above 500 μg (1.69 μmol) per plate for all five strains in the presence and absence of S9 mix. There was no evidence of cytotoxicity as indicated by reductions in the growth of the background lawns or in the incidence of spontaneous revertant colonies.

Experiment 2 (pre-incubation method): Eight to ten test item dose levels were selected in Experiment 2 in order to achieve both a minimum of four non-toxic doses and the toxic/guideline limit of the test item. The dose levels were selected based on the results of Experiment 1.
All strains (presence of S9-mix): 0, 0.5, 1.6, 5, 16, 50, 160, 500 and 1600 µg/plate
All strains (absence of S9-mix): 0, 0.5, 1.6, 5, 16, 50, 160, 500 and 1600 µg/plate
On the day of dosing, precipitate was seen at and above 160 μg (0.54 μmol) per plate for all five strains in the presence and absence of S9 mix. On the day of scoring, precipitate was seen at and above 500 μg (1.69 μmol) per plate for all five strains in the presence and absence of S9 mix. There was no evidence of cytotoxicity as indicated by reductions in the growth of the background lawns or in the incidence of spontaneous revertant colonies.
Vehicle / solvent:
- Vehicle(s)/solvent(s) used: dimethylsulphoxide (DMSO)
- Justification for choice of solvent/vehicle: The test item was miscible in DMSO at 100 mg/mL in solubility checks performed. DMSO was selected as the vehicle as a preferred solvent according to guideline(s).
- Other: Formulated concentrations would be adjusted/increased to allow for the stated water/impurity content, as applicable.. See 'Test Material Information' for further details, as applicable.
Controlsopen allclose all
Untreated negative controls:
yes
Negative solvent / vehicle controls:
yes
True negative controls:
no
Positive controls:
yes
Positive control substance:
9-aminoacridine
2-nitrofluorene
sodium azide
other: Potassium dichromate
Remarks:
Without metabolic activation S9
Untreated negative controls:
yes
Negative solvent / vehicle controls:
yes
True negative controls:
no
Positive controls:
yes
Positive control substance:
other: 2-Aminoanthracene
Remarks:
With metabolic activation S9 ; Each batch was subjected to in-house testing to assess batch-to-batch variation using promutagens: cyclophosphamide and benzo[a]pyrene (TA1535 and TA98, respectively) and was found to be acceptable.
Details on test system and experimental conditions:
METHOD OF APPLICATION: Experiment 1. in medium; in agar (plate incorporation) ; Experiment 2. in medium; in agar (pre-incubation).
The test item was administered in solvent (DMSO) at a volume of 100 μL per plate for the plate incorporation method and a volume of 50 μL per plate when the liquid pre-incubation method was employed, within a maximum of two hours of formulation. For each test, a stock solution of test item in the solvent, DMSO, was prepared and then diluted in the same solvent to formulate the required test solutions. The solutions of test 1: A: 50 mg/mL (or 169 mmol/L) through H: 0.016 mg/mL (or 0.054 mmol/L) ; test 2: I: 32 mg/mL (or 54 mmol/L) through P: 0.01 mg/mL (or 0.0169 mmol/L) are documented in the full study report.

DURATION
- Exposure duration:
Experiment 1 (plate incorporation method) : Briefly, frozen aliquots of the bacterial strains (-70°C or lower) were incubated overnight (8 to 10 hours) at 37°C in an orbital incubator (120 rpm) in nutrient broth. For strains TA98, TA100 and uvrA/pKM101, the nutrient broth was supplemented with ampicillin at 25 μg/mL. Aliquots (100 μL each) of bacterial culture were mixed with 100 μL of solvent, positive control or test formulation dilution and 500 μL of sodium phosphate buffer or S9 mix. Finally, 2 mL of molten 0.6% agar maintained at approximately 50°C and supplemented with low concentrations of biotin and histidine (each at 0.05 mmol/L) for the S. typhimurium strains, and tryptophan (0.018 mmol/L) for the E. coli strain, was added. The mixture was immediately poured onto minimal glucose agar plates and incubated for 3 days at 37°C. There were three plates in all solvent control, test item and positive control groups. After incubation at 37°C for 3 days, all plates were examined both macroscopically and microscopically for evidence of cytotoxicity, precipitates and any other effect relevant to the interpretation of the test. Microscopic examination was used to check the condition of the histidine/tryptophan-requiring microcolonies that make up the background lawns. Revertant (his+, trp+) colony numbers were scored using a Sorcerer Colony Counter. Manual counts may be performed, where automated counting cannot be performed: e.g. colonies spreading, colonies on the edge of the plates and artefacts on the plates, thus distorting the actual plate count.
Experiment 2 (pre-incubation method) : Aliquots (100 μL each) of bacterial culture were mixed with 50 μL of solvent, positive control or test item formulation dilution and 500 μL of sodium phosphate buffer or S9 mix and then incubated for 60 minutes at 37°C in an orbital incubator at 120 rpm. After incubation, 2 mL of molten 0.6% agar containing biotin and histidine/tryptophan (as above) was added to the mixture and poured onto minimal glucose agar plates and incubated for a further 3 days at 37°C. There were three plates in all solvent control, test item and positive control groups. After incubation at 37°C for 3 days, all plates were examined both macroscopically and microscopically for evidence of cytotoxicity, precipitates and any other effect relevant to the interpretation of the test. Microscopic examination was used to check the condition of the histidine/tryptophan-requiring microcolonies that make up the background lawns. Revertant (his+, trp+) colony numbers were scored using a Sorcerer Colony Counter. Manual counts may be performed, where automated counting cannot be performed: e.g. colonies spreading, colonies on the edge of the plates and artefacts on the plates, thus distorting the actual plate count.

SELECTION AGENT (mutation assays): histidine or tryptophan -deficient agar

NUMBER OF REPLICATIONS: 3

DETERMINATION OF CYTOTOXICITY
- Method: relative total growth
- Other: Viability determination: Confirmation that adequate numbers of viable bacteria were exposed to the test item was obtained from viability determinations for each strain performed concurrently with the mutagenicity test. For each tester strain, a sample of the stock overnight bacterial suspension was diluted to 1x10^-7 in phosphate buffered saline. 200 μL of the x10^-7 dilution was spread onto each of two nutrient agar plates. The plates were then inverted and incubated at room temperature for 3 days, after which, numbers of colonies were counted and recorded. A mean viable count of at least 20 colonies per plate should be present (>10^9 colony forming units [cfu] per mL).
Rationale for test conditions:
In accordance with the OECD TG 471 guidelines.
Evaluation criteria:
There are several criteria for determining a positive result. Any, one, or all of the following can be used to determine the overall result of the study:
1. A dose-related increase in mutant frequency over the dose range tested
2. A reproducible increase at one or more concentrations.
3. Biological relevance against in-house historical control ranges.
4. Statistical analysis of data
5. For TA1535 or TA1537, the mean number of revertant colonies of one or more doses of the test item, with or without metabolic activation was equal to or greater than 3 times the concurrent solvent control mean value (2-fold increases outside the historical control range may be assessed as equivocal); for any other strain, the mean number of revertant colonies was equal to or greater than 2 times the concurrent solvent control mean value in the presence of one or more doses of the test item, with or without metabolic activation.
A test item is considered non-mutagenic (negative) in the test system if the above criteria are not met.
In instances of data prohibiting definitive judgement about test item activity are reported as equivocal.

Results and discussion

Test resultsopen allclose all
Key result
Species / strain:
S. typhimurium TA 98
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
cytotoxicity
Remarks:
See table 1 and 2
Vehicle controls validity:
valid
Untreated negative controls validity:
valid
Positive controls validity:
valid
Key result
Species / strain:
S. typhimurium TA 100
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
cytotoxicity
Remarks:
See table 1 and 2
Vehicle controls validity:
valid
Untreated negative controls validity:
valid
Positive controls validity:
valid
Key result
Species / strain:
S. typhimurium TA 1535
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
cytotoxicity
Remarks:
See table 1 and 2
Vehicle controls validity:
valid
Untreated negative controls validity:
valid
Positive controls validity:
valid
Key result
Species / strain:
S. typhimurium TA 1537
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
cytotoxicity
Remarks:
See table 1 and 2
Vehicle controls validity:
valid
Untreated negative controls validity:
valid
Positive controls validity:
valid
Key result
Species / strain:
E. coli WP2 uvr A pKM 101
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
cytotoxicity
Remarks:
See table 1 and 2
Vehicle controls validity:
valid
Untreated negative controls validity:
valid
Positive controls validity:
valid
Additional information on results:
HISTORICAL CONTROL DATA (with ranges, means and standard deviation and confidence interval (e.g. 95%)
- Positive historical control data: The current Positive HCD dataset is presented in the full study report.
- Negative (solvent/vehicle) historical control data: The current background spontaneous revertant counts in concurrent untreated controls and/or or vehicle controls ; historic negative controls are presented in the full study report.

Any other information on results incl. tables

Table 1 : Test Results: Experiment 1 with and without metabolic activation and results of concurrent positive controls

S9-Mix

(+)

Dose Level

Per Plate

Number ofrevertants(mean) +/- SD

TA98

TA100

TA1535

TA1537

WP2uvrA/pKM101

Solvent Control

(DMSO)

40

32

37

(36)

4.0#

159

153

159

(157)

3.5

14

14

10

(13)

2.3

12

12

9

(11)

1.7

181

188

190

(186)

4.7

1.6 µg

39

40

39

(39)

0.6

1.1~

163

157

168

(163)

5.5

1.0

13

12

11

(12)

1.0

0.9

11

12

10

(11)

1.0

1.0

175

212

185

(191)

19.1

1.0

5 µg

35

36

29

(33)

3.8

0.9

159

155

163

(159)

4.0

1.0

15

12

11

(13)

2.1

1.0

11

10

11

(11)

0.6

1.0

201

178

200

(193)

13.0

1.0

16 µg

37

34

27

(33)

5.1

0.9

143

137

149

(143)

6.0

0.9

10

14

9

(11)

2.6

0.8

10

11

13

(11)

1.5

1.0

195

164

193

(184)

17.3

1.0

50 µg

39

37

36

(37)

1.5

1.0

149

141

157

(149)

8.0

0.9

10

11

14

(12)

2.1

0.9

10

12

11

(11)

1.0

1.0

198

189

190

(192)

4.9

1.0

160 µg

35

39

39

(38)

2.3

1.1

157

147

141

(148)

8.1

0.9

11

9

11

(10)

1.2

0.8

12

13

11

(12)

1.0

1.1

173

163

162

(166)

6.1

0.9

500 µg

41 P

37 P

29 P

(36)

6.1

1.0

149 P

152 P

144 P

(148)

4.0

0.9

13 P

12 P

13 P

(13)

0.6

1.0

12 P

13 P

10 P

(12)

1.5

1.1

157 P

181 P

185 P

(174)

15.1

0.9

1600 µg

29 P

27 P

32 P

(29)

2.5

0.8

148 P

154 P

144 P

(149)

5.0

0.9

11 P

13 P

12 P

(12)

1.0

0.9

11 P

12 P

10 P

(11)

1.0

1.0

142 P

138 P

104 P

(128)

20.9

0.7

5000 µg

31 P

35 P

27 P

(31)

4.0

0.9

132 P

116 P

135 P

(128)

10.2

0.8

8 P

8 P

12 P

(9)

2.3

0.7

8 P

7 P

12 P

(9)

2.6

0.8

138 P

169 P

121 P

(143)

24.3

0.8

Positive controls

S9-Mix

(+)

Name

Dose Level

No. ofRevertants

2AA

2AA

2AA

2AA

2AA

2 µg

2 µg

2 µg

2 µg

20 µg

1507

1517

1390

(1471)

70.6#

40.9~

1313

1705

1736

(1585)

235.8

10.1

170

210

217

(199)

25.4

15.3

148

152

137

(146)

7.8

13.3

2879

2694

2567

(2713)

156.9

14.6

S9-Mix

(-)

Dose Level

Per Plate

Number ofrevertants(mean) +/- SD

TA98

TA100

TA1535

TA1537

WP2uvrA/pKM101

Solvent Control

(DMSO)

31

27

31

(30)

2.3#

118

119

119

(119)

0.6

13

12

16

(14)

2.1

10

10

12

(11)

1.2

164

160

145

(156)

10.0

1.6 µg

27

30

24

(27)

3.0

0.9~

126

128

109

(121)

10.4

1.0

12

14

13

(13)

1.0

0.9

11

9

10

(10)

1.0

0.9

133

154

170

(152)

18.2

1.0

5 µg

31

30

32

(31)

1.0

1.0

118

122

114

(118)

4.0

1.0

14

14

12

(13)

1.2

0.9

9

11

12

(11)

1.5

1.0

165

169

170

(168)

2.6

1.1

16 µg

24

29

29

(27)

2.9

0.9

119

119

116

(118)

1.7

1.0

11

11

12

(11)

0.6

0.8

8

10

9

(9)

1.0

0.8

159

145

130

(145)

14.5

0.9

50 µg

32

32

26

(30)

3.5

1.0

121

122

122

(122)

0.6

1.0

12

13

14

(13)

1.0

0.9

11

10

10

(10)

0.6

0.9

157

149

145

(150)

6.1

1.0

160 µg

31

26

26

(28)

2.9

0.9

118

123

118

(120)

2.9

1.0

13

12

12

(12)

0.6

0.9

10

11

10

(10)

0.6

0.9

157

145

130

(144)

13.5

0.9

500 µg

31 P

30 P

31 P

(31)

0.6

1.0

119 P

114 P

117 P

(117)

2.5

1.0

10 P

12 P

15 P

(12)

2.5

0.9

11 P

11 P

11 P

(11)

0.0

1.0

166 P

159 P

136 P

(154)

15.7

1.0

1600 µg

29 P

24 P

30 P

(28)

3.2

0.9

112 P

124 P

121 P

(119)

6.2

1.0

13 P

12 P

11 P

(12)

1.0

0.9

10 P

9 P

11 P

(10)

1.0

0.9

133 P

142 P

130 P

(135)

6.2

0.9

5000 µg

32 P

27 P

29 P

(29)

2.5

1.0

118 P

119 P

113 P

(117)

3.2

1.0

13 P

13 P

13 P

(13)

0.0

0.9

10 P

12 P

10 P

(11)

1.2

1.0

153 P

147 P

169 P

(156)

11.4

1.0

Positive controls

S9-Mix

(-)

Name

Dose Level

No. ofRevertants

2-nitrofluorene

Naazide

Naazide

9AA

K2Cr2O7

1 µg

0.5 µg

0.5 µg

50 µg

25 µg

375

348

333

(352)

21.3#

11.7~

656

587

632

(625)

35.0

5.3

511

457

488

(485)

27.1

34.6

267

219

261

(249)

26.2

22.6

1347

1274

1320

(1314)

36.9

8.4

N/T: Not tested at this dose level

s: slightly reduced lawn

r: reduced lawn

v: very reduced lawn

n: no survival

f: pseudorevertants

P: Precipitate

#: Standard deviation

~: fold increase over solvent control

 

Table 2 : Test Results: Experiment 2 with and without metabolic activation and results of concurrent positive controls

S9-Mix

(+)

Dose Level

Per Plate

Number ofrevertants(mean) +/- SD

TA98

TA100

TA1535

TA1537

WP2uvrA/pKM101

Solvent Control

(DMSO)

37

32

34

(34)

2.5#

152

160

154

(155)

4.2

12

12

12

(12)

0.0

12

10

11

(11)

1.0

203

188

167

(186)

18.1

0.5 µg

32

34

36

(34)

2.0

1.0~

144

158

148

(150)

7.2

1.0

10

11

11

(11)

0.6

0.9

12

10

13

(12)

1.5

1.1

174

177

170

(174)

3.5

0.9

1.6 µg

31

37

30

(33)

3.8

1.0

171

150

169

(163)

11.6

1.1

11

11

10

(11)

0.6

0.9

11

11

10

(11)

0.6

1.0

169

173

200

(181)

16.9

1.0

5 µg

36

37

30

(34)

3.8

1.0

160

149

142

(150)

9.1

1.0

12

12

12

(12)

0.0

1.0

11

11

10

(11)

0.6

1.0

189

200

199

(196)

6.1

1.1

16 µg

35

37

31

(34)

3.1

1.0

152

164

142

(153)

11.0

1.0

13

14

15

(14)

1.0

1.2

11

9

10

(10)

1.0

0.9

199

195

211

(202)

8.3

1.1

50 µg

31

35

30

(32)

2.6

0.9

150

148

132

(143)

9.9

0.9

12

13

12

(12)

0.6

1.0

11

11

11

(11)

0.0

1.0

198

160

181

(180)

19.0

1.0

160 µg

32

34

31

(32)

1.5

0.9

140

137

150

(142)

6.8

0.9

10

9

10

(10)

0.6

0.8

12

10

13

(12)

1.5

1.1

183

161

212

(185)

25.6

1.0

500 µg

33 P

35 P

29 P

(32)

3.1

0.9

155 P

142 P

145 P

(147)

6.8

0.9

13 P

13 P

12 P

(13)

0.6

1.1

12 P

11 P

12 P

(12)

0.6

1.1

176 P

184 P

174 P

(178)

5.3

1.0

1600 µg

35 P

39 P

32 P

(35)

3.5

1.0

144 P

159 P

140 P

(148)

10.0

1.0

14 P

10 P

10 P

(11)

2.3

0.9

10 P

8 P

11 P

(10)

1.5

0.9

181 P

204 P

164 P

(183)

20.1

1.0

Positive controls

S9-Mix

(+)

Name

Dose Level

No. ofRevertants

2AA

2AA

2AA

2AA

2AA

2 µg

2 µg

2 µg

2 µg

20 µg

1992

1417

2060

(1823)

353.2#

53.6~

2240

2009

2132

(2127)

115.6

13.7

189

226

178

(198)

25.1

16.5

208

198

211

(206)

6.8

18.7

1535

1366

1610

(1504)

125.0

8.1

S9-Mix

(-)

Dose Level

Per Plate

Number ofrevertants(mean) +/- SD

TA98

TA100

TA1535

TA1537

WP2uvrA/pKM101

Solvent Control

(DMSO)

35

29

29

(31)

3.5#

123

116

119

(119)

3.5

15

13

12

(13)

1.5

10

9

10

(10)

0.6

165

175

158

(166)

8.5

0.5 µg

30

30

27

(29)

1.7

0.9~

119

121

128

(123)

4.7

1.0

14

12

13

(13)

1.0

1.0

10

8

9

(9)

1.0

0.9

153

180

165

(166)

13.5

1.0

1.6 µg

27

29

29

(28)

1.2

0.9

116

112

122

(117)

5.0

1.0

13

12

10

(12)

1.5

0.9

8

9

11

(9)

1.5

0.9

145

166

174

(162)

15.0

1.0

5 µg

31

26

24

(27)

3.6

0.9

116

118

126

(120)

5.3

1.0

11

12

10

(11)

1.0

0.8

10

8

9

(9)

1.0

0.9

158

173

164

(165)

7.5

1.0

16 µg

32

31

27

(30)

2.6

1.0

127

129

115

(124)

7.6

1.0

14

10

11

(12)

2.1

0.9

9

9

11

(10)

1.2

1.0

168

159

171

(166)

2.5

0.8

50 µg

29

26

31

(29)

2.5

0.9

122

126

121

(123)

2.6

1.0

10

12

8

(10)

2.0

0.8

10

9

11

(10)

1.0

1.0

153

171

143

(156)

14.2

0.9

160 µg

32

24

25

(27)

4.4

0.9

126

116

119

(120)

5.1

1.0

12

12

13

(12)

0.6

0.9

8

8

9

(8)

0.6

0.8

137

164

173

(158)

18.7

1.0

500 µg

31 P

25 P

32 P

(29)

3.8

0.9

121 P

127 P

119 P

(122)

4.2

1.0

10 P

11 P

12 P

(11)

1.0

0.8

9 P

11 P

8 P

(9)

1.5

0.9

158 P

186 P

160 P

(168)

15.6

1.0

1600 µg

31 P

31 P

29 P

(30)

1.2

1.0

118 P

118 P

119 P

(118)

0.6

1.0

12 P

9 P

10 P

(10)

1.5

0.8

9 P

11 P

8 P

(9)

1.5

0.9

162 P

180 P

171 P

(171)

9.0

1.0

Positive controls

S9-Mix

(-)

Name

Dose Level

No. ofRevertants

2-nitrofluorene

Naazide

Naazide

9AA

K2Cr2O7

1 µg

0.5 µg

0.5 µg

50 µg

25 µg

1377

1172

1235

(1261)

105.0#

40.7~

501

496

473

(490)

14.9

4.1

352

358

334

(348)

12.5

26.8

137

158

126

(140)

16.3

14.0

899

898

1036

(944)

79.4

5.7

N/T: Not tested at this dose level

s: slightly reduced lawn

r: reduced lawn

v: very reduced lawn

n: no survival

f: pseudorevertants

P: Precipitate

#: Standard deviation

~: fold increase over solvent control

Applicant's summary and conclusion

Conclusions:
Interpretation of results:
negative
Under the conditions of this study, the test item was considered to be non-mutagenic in the presence and absence of S9 activation.
Executive summary:

The study was performed to the requirements of OECD Guideline 471 under GLP, to evaluate the potential mutagenicity of the test item in a bacterial reverse mutation assay using S.typhimurium strains TA98, TA100, TA1535, TA1537 and E.coli strain WP2 uvrA/pKM101 as indicator organisms in both the presence and absence of S-9 mix. The test strains were treated with the test item using the Ames (i) plate incorporation method and then (ii) pre incubation method at up to eight dose levels, in triplicate, both with and without the addition of a rat liver homogenate metabolizing system (10% liver S9 in standard co-factors). A preliminary solubility assessment was conducted. As solubility was satisfactory in dimethyl sulphoxide, it was used throughout this study as the solvent for the test item. The dose range for Experiment 1 (plate incorporation method) was predetermined and was 1.6 to 5000 µg/plate (or 0.0054 to 16.9 μmol per plate) for all five indicator strains in both the presence and absence of an in vitro activation system based on S9 fraction obtained from Aroclor 1254-induced rat liver (S9 mix). The experiment was repeated in Experiment 2 (preincubation method) on a separate day using fresh cultures of the bacterial strains and fresh test item formulations. Up to eight test item dose levels were selected in Experiment 2 in order to achieve a minimum of four non-toxic dose levels and the toxic limit of the test item. The dose range employed was between 0.5 and 1600 µg/plate (or 0.00169 to 5.4 μmol per plate), in the presence or absence of S9-mix. The test item showed no evidence of cytotoxicity as indicated by reductions in the growth of the background lawns or in the incidence of spontaneous revertant colonies. The maximum dose level scored for revertant colonies was 5000 μg (16.9 μmol) per plate. The minimum dose at which precipitate was seen was 500 μg (1.69 μmol) per plate. More specifically, the maximum dose level of the test item in experiment 1 was selected as the maximum recommended dose level of 5000 μg/plate or the toxic limit of the test item depending on the strain type and presence of S9-mix. The maximum dose level in experiment 2 was selected on the basis that, for non-cytotoxic substances that are not soluble at 5000 μg/plate, one or more concentrations tested should be insoluble in the final treatment mixture (i.e. precipitating dose level). This was requirement was achieved in experiment 2, using a maximum dose level of 1600 µg/plate, in the presence or absence of S9-mix. The vehicle (DMSO) control plates gave counts of revertant colonies within the normal range. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with or without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated. In both experiments there were no significant increase in numbers of revertant (histidine or tryptophan-independent) colonies was seen with any of the five indicator strains either in the presence or absence of S9 mix. It was concluded that, under the conditions of this assay, the test item gave a negative, i.e. non-mutagenic response in S.typhimurium strains TA98, TA100, TA1535, TA1537 and E.coli strain WP2 uvrA/pKM101 in the presence and absence of S-9 mix.